<i>In vitro</i> maturation of immature oocytes for fertility preservation in cancer patients compared to control patients with fertility problems in an <i>in vitro</i> fertilization program

Virant‐Klun, Irma; Bedenk, Jure; Jančar, Nina

doi:10.2478/raon-2021-0053

Cited by 9 publications

(4 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…102 103 104 It has been shown that measuring serum AMH level can be used as a predictive marker for the success of IVM, influencing outcomes such as the number of mature oocytes obtained and the overall efficiency of the maturation process. 103 105 However, in women with cancer, oocyte maturation rates are lower than that in healthy women, 106 so this technique seems to be of more interest when pretreatment AMH level is high (>3.7 ng/mL) in order to obtain a minimum of 10 mature oocytes after IVM. 105 Thus, serum AMH level could be used to select women to be offered IVM technique.…”

Section: Amh and Art Outcome For Fertility Preservation: How Useful I...mentioning

confidence: 99%

Anti-Mullerian Hormone Assessment in Assisted Reproductive Technique Outcome and Natural Conception

Sellami,

Barbotin,

Bernard

et al. 2024

Semin Reprod Med

View full text Add to dashboard Cite

In recent years, the prevalence of infertility has increased, and appears to affect approximately one in six couples. Some of them must perform assisted reproductive techniques (ART) in order to achieve pregnancy. As a result, growing interest has arisen about predictive factors of pregnancy and live birth with and without ART. Anti-Mullerian hormone (AMH) is a glycoprotein discovered in the 1950s in male embryonic sexual differentiation. Later, in 1984, its role in folliculogenesis was reported: secreted by granulosa cells, this hormone is involved in the regulation of the recruitment of primordial follicles and in follicular growth. AMH assays were developed for women in 1990s, and the serum AMH level has rapidly become a crucial element in managing women's fertility. Based mainly on its ability to be a quantitative but indirect marker of ovarian reserve, the serum AMH assay is widely used in reproductive medicine and ART. This review summarizes current knowledge of the AMH assessment in the field of reproductive medicine. We focus on the role of AMH level to predict spontaneous pregnancy occurrence, ART outcomes, and fertility preservation outcomes.

show abstract

Section: Amh and Art Outcome For Fertility Preservation: How Useful I...mentioning

confidence: 99%

Anti-Mullerian Hormone Assessment in Assisted Reproductive Technique Outcome and Natural Conception

Sellami,

Barbotin,

Bernard

et al. 2024

Semin Reprod Med

View full text Add to dashboard Cite

show abstract

“…Therefore, although most centers adopt this protocol, labeled as IVF/M cycles, the outcome remains low to be translated into clinical pregnancy, although utilized among normal ovarian reserve women ( 31 ). Nevertheless, it can be reserved as an alternative fertility preservation (FP) strategy, primarily for women with a limited stimulation window, such as patients with cancer aiming for more mature oocytes for future use ( 32 ). Thus, utilizing IVM protocol in cycles that potentially harvest both immature and mature oocytes in the same cycle and using the hcg trigger are currently not considered standard IVM because not all oocytes were mature in vitro per se ( 10 , 22 ).…”

Section: Controversial Definition Of In Vitro Matu...mentioning

confidence: 99%

The spectrum of in vitro maturation in clinical practice: the current insight

et al. 2023

View full text Add to dashboard Cite

In vitro oocyte maturation (IVM) has been used worldwide. Despite the long-term implementation, the uptake of this procedure to complement current in vitro fertilization (IVF) remains low. The main reason is likely due to the non-synchronization of protocol and definition criteria, leading to difficulty in collective proper outcome data worldwide and, thus, lack of understanding of the exact IVM procedure. The review aims to consolidate the current clinical practice of IVM by dissecting relevant publications to be tailored for a current spectrum of clinical practice. Nevertheless, the background theories of oocyte maturation were also explored to provide a comprehensive understanding of the basis of IVM theories. Additional discussion of other potential uses of IVM in the future, such as in ovarian tissue cryopreservation known as OTO-IVM for fertility preservation and among women with diminished ovarian reserve, was also explored. Otherwise, future collaboration among all IVM centers is paramount for better collection of clinical data to provide valid recommendations for IVM in clinical practice, especially in molecular integrity and possible DNA alteration if present for IVM offspring outcome safety purposes.

show abstract

“…Furthermore, this study compared the number of mature oocytes obtained through IVM in groups of patients with different types of cancer and fertility problems. The results indicated that patients with breast cancer had a lower proportion of oocytes that matured in vitro compared to patients with other cancers and those with fertility problems (54.5% vs. 81.2% and 80.0%) [103,104]. In 2020, Malacarne et al [105] arrived at the conclusion that there was no significant difference in the mean number of oocytes retrieved for each breast cancer patient following ovarian stimulation, as compared to healthy control women, including oocyte donors, women undergoing fertility preservation for nonmedical reasons, and female partners of infertile men participating in an in vitro fertilization (IVF) program.…”

Section: In Vitro Maturation (Ivm)mentioning

confidence: 99%

Breast Cancer and Fertility Preservation in Young Female Patients: A Systematic Review of the Literature

Boutas,

Kontogeorgi,

Koufopoulos

et al. 2023

Clinics and Practice

View full text Add to dashboard Cite

Introduction: Breast cancer affects almost 1.5 million women worldwide below the age of 45 years each year. Many of these women will be advised to undergo adjuvant chemotherapy to minimize the risk of death or recurrence of the tumor. For these patients, chemotherapy is a known cause of infertility, as it can damage primordial follicles, which can lead to early menopause or premature ovarian insufficiency. This systematic review aims to synthesize the current evidence of the most suitable treatments for fertility preservation. Methodology: This review was performed following the PRISMA guidelines. The authors conducted an extensive search from the last 15 years. Relevant studies were pursued in PubMed, Embase, and the Cochrane Library up until 31 July 2023. A total of seven eligible studies were identified. Results: From the reviewed literature, ovarian suppression with gonadotropin-releasing hormone agonists showed promising results in preserving fertility for breast cancer patients undergoing chemotherapy. Additionally, oocyte and embryo cryopreservation demonstrated successful outcomes, with embryo cryopreservation being the most effective option. Notably, the slow-freezing and vitrification methods were both effective in preserving embryos, with vitrification showing superior results in clinical-assisted reproductive technologies. Ovarian tissue cryopreservation emerged as a viable option for prepubertal girls and those unable to undergo conventional ovarian stimulation. The potential of in vitro maturation (IVM) as an alternative method presents a promising avenue for future fertility preservation research. Discussion: The most suitable treatments for fertility preservation in young patients is the temporary suppression with luteinizing hormone-releasing analogs, while the patient undergoes chemotherapy and cryopreservation. For cryopreservation, the physicians might deem it necessary to either cryopreserve ovarian tissue taken from the patient before any treatment or cryopreserve embryos/oocytes. Cryopreservation of oocytes and/or embryos is the most effective solution for fertility preservation in women of reproductive age, who have a sufficient ovarian reserve and are diagnosed with breast cancer, regardless of the histological type of the tumor. Because approximately 50% of young breast cancer patients are interested in becoming pregnant right after completion of therapy, the evolution and development of fertility preservation techniques promise to be very exciting.

show abstract

In vitro maturation of immature oocytes for fertility preservation in cancer patients compared to control patients with fertility problems in an in vitro fertilization program

Cited by 9 publications

References 57 publications

Anti-Mullerian Hormone Assessment in Assisted Reproductive Technique Outcome and Natural Conception

Anti-Mullerian Hormone Assessment in Assisted Reproductive Technique Outcome and Natural Conception

The spectrum of in vitro maturation in clinical practice: the current insight

Breast Cancer and Fertility Preservation in Young Female Patients: A Systematic Review of the Literature

Contact Info

Product

Resources

About